

Lexaria Bioscience Corp.

08:55 16 Jul 2020

Lexaria Bioscience finalizes first phase of research program on DehydraTECH oral nicotine formulation with Altria Ventures

Lexaria Bioscience Corp (OTCQX:LXRP) (CSE:LXX) has concluded Phase I of a research program with Altria Ventures Inc that examined oral methods of nicotine delivery.

The research program utilized Lexaria's patented DehydraTECH technology, which increases bio-absorption by up to 10 times and reduces the time of onset to minutes while masking unwanted taste.

According to the findings, the oral nicotine formulation demonstrated "acceptable" chemical and microbiological stability and saw no issues with throat irritation in oral pouch and chew formats at standard commercial doses.

READ: Lexaria Bioscience applies for grant for coronavirus therapy studies and receives new expanded Health Canada license

The formulation showed no adverse effect on survival or organ weights in a seven-day, repeat-dose acute toxicology study in rats, and no test article-related histopathological tissue findings, the group noted.

The early-stage DehydraTECH formulation formed a unique mixture of nanoparticles without forming a covalently linked, new molecular entity construct upon molecular characterization by Canada's National Research Council (NRC), which Lexaria said should not prevent a Premarket Tobacco Product Application.

"The findings from this Phase I research and development program deliver many valuable insights about our DehydraTECH technology," said Chris Bunka, CEO of Lexaria in a statement. "We are pleased to have concluded the Phase I scientific program and we thank the joint researchers at both Altria and the NRC for their collaboration together with our own scientists."

The Vancouver-based firm said it was "highly positive" regarding the commercial future of DehydraTECH.

Altria agreement


Lexaria and Altria Ventures, a wholly-owned subsidiary of tobacco giant Altria Group Inc (NYSE:MO), first partnered in January 2019 to pursue research in oral, reduced risk nicotine consumer products. Altria is funding a milestone-based research and development program in exchange for a minority equity interest in Lexaria's subsidiary Lexaria Nicotine and certain DehydraTECH license rights.

As part of the agreement, Altria may exercise its first tranche of warrants in Lexaria Nicotine by way of another staged payment to the subsidiary, which would allow Altria to maintain its current exclusivity over DehydraTECH for oral nicotine delivery in the US.

Price: 0.33

Market Cap: \$29.56 m

1 Year Share Price Graph



September 2019 March 2020 September 2020

Share Information

Code: LXX

Listing: CSE

52 week High Low
0.99 0.31

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i.e.

action@proactiveinvestors.com

Regardless of whether Altria exercises the first warrant tranche, Altria maintains its existing minority equity stake and board representation in Lexaria Nicotine as well as a non-exclusive license to use DehydraTECH worldwide outside of the US. The firm also agreed to an earlier-defined royalty payment schedule to Lexaria in the event it decides to utilize the technology commercially.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).